Sawgrass Asset Management LLC Sells 4,104 Shares of Zoetis Inc. (NYSE:ZTS)

Sawgrass Asset Management LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,638 shares of the company’s stock after selling 4,104 shares during the period. Sawgrass Asset Management LLC’s holdings in Zoetis were worth $10,857,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Pensionfund Sabic lifted its holdings in shares of Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC acquired a new position in Zoetis in the fourth quarter valued at $1,764,000. JPMorgan Chase & Co. raised its holdings in shares of Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Zoetis during the third quarter valued at about $11,684,000. Finally, Nordea Investment Management AB raised its holdings in shares of Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after purchasing an additional 572,511 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Zoetis Stock Down 0.2 %

ZTS opened at $173.99 on Thursday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market cap of $78.50 billion, a price-to-earnings ratio of 32.70, a PEG ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company’s 50-day moving average price is $169.11 and its two-hundred day moving average price is $179.11.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective on the stock. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partners began coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Piper Sandler decreased their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $214.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.